PMC:7228307 / 43359-43448 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"814","span":{"begin":57,"end":61},"obj":"Gene"},{"id":"819","span":{"begin":14,"end":19},"obj":"Gene"},{"id":"831","span":{"begin":42,"end":47},"obj":"Mutation"}],"attributes":[{"id":"A814","pred":"tao:has_database_id","subj":"814","obj":"Gene:2213"},{"id":"A819","pred":"tao:has_database_id","subj":"819","obj":"Gene:29126"},{"id":"A831","pred":"tao:has_standard_notation","subj":"831","obj":"p.N297A"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T770","span":{"begin":14,"end":19},"obj":"http://purl.obolibrary.org/obo/CLO_0008407"},{"id":"T771","span":{"begin":57,"end":59},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T224","span":{"begin":14,"end":16},"obj":"Chemical"}],"attributes":[{"id":"A224","pred":"chebi_id","subj":"T224","obj":"http://purl.obolibrary.org/obo/CHEBI_74756"}],"text":"Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"814","span":{"begin":57,"end":61},"obj":"Gene"},{"id":"819","span":{"begin":14,"end":19},"obj":"Gene"},{"id":"831","span":{"begin":42,"end":47},"obj":"Mutation"}],"attributes":[{"id":"A814","pred":"pubann:denotes","subj":"814","obj":"Gene:2213"},{"id":"A819","pred":"pubann:denotes","subj":"819","obj":"Gene:29126"},{"id":"A831","pred":"pubann:has_HGVS_notation","subj":"831","obj":"p.N297A"}],"text":"Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T246","span":{"begin":0,"end":89},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T444","span":{"begin":14,"end":19},"obj":"Protein"}],"attributes":[{"id":"A444","pred":"uniprot_id","subj":"T444","obj":"https://www.uniprot.org/uniprot/Q9NZQ7"},{"id":"A445","pred":"uniprot_id","subj":"T444","obj":"https://www.uniprot.org/uniprot/Q9NUZ5"},{"id":"A446","pred":"uniprot_id","subj":"T444","obj":"https://www.uniprot.org/uniprot/Q9EP73"},{"id":"A447","pred":"uniprot_id","subj":"T444","obj":"https://www.uniprot.org/uniprot/Q6WEX4"},{"id":"A448","pred":"uniprot_id","subj":"T444","obj":"https://www.uniprot.org/uniprot/Q66RK1"},{"id":"A449","pred":"uniprot_id","subj":"T444","obj":"https://www.uniprot.org/uniprot/Q2V8D5"},{"id":"A450","pred":"uniprot_id","subj":"T444","obj":"https://www.uniprot.org/uniprot/Q14CJ2"},{"id":"A451","pred":"uniprot_id","subj":"T444","obj":"https://www.uniprot.org/uniprot/B4DU27"},{"id":"A452","pred":"uniprot_id","subj":"T444","obj":"https://www.uniprot.org/uniprot/B2RBA2"}],"text":"Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed"}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T18","span":{"begin":71,"end":79},"obj":"Phenotype"}],"attributes":[{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed"}

{"project":"LitCovid-sentences","denotations":[{"id":"T246","span":{"begin":0,"end":89},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T18","span":{"begin":71,"end":79},"obj":"Phenotype"}],"attributes":[{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed"}